Global Bio-chem Technology Group Company Limited Logo

Global Bio-chem Technology Group Company Limited

0809.HK

(1.8)
Stock Price

0,07 HKD

84.94% ROA

-122.71% ROE

0.16x PER

Market Cap.

650.240.930,00 HKD

-99.16% DER

0% Yield

256.63% NPM

Global Bio-chem Technology Group Company Limited Stock Analysis

Global Bio-chem Technology Group Company Limited Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Global Bio-chem Technology Group Company Limited Fundamental Stock Analysis
# Analysis Rating
1 ROE

ROE surpassing expectations (21.62%) highlights strong profitability and efficient use of shareholders' equity, making it an appealing investment prospect.

2 PBV

With a remarkably low PBV ratio (-0.06x), the stock offers substantial upside potential at a bargain price.

3 DER

The stock has a minimal amount of debt (-108%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

4 Graham Number

The company's Graham number indicates that it is undervalued compared to its stock price, suggesting a potentially favorable investment opportunity.

5 ROA

The stock's ROA (-25.99%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

6 Revenue Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

7 Net Profit Growth

Throughout the last five years, this company's net profit has remained unchanged, indicating a lack of growth and making it a less favorable investment option.

8 Assets Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

9 Dividend Growth

The company's dividend growth has remained unchanged for three years, signaling a lack of positive momentum and making it a less favorable investment choice.

10 Dividend

The company's lack of dividends in the past three years may concern investors seeking regular income.

11 Buffet Intrinsic Value

The company's stock shows signs of being overvalued (0) according to Warren Buffett's formula, indicating a potential downside as its market price exceeds its estimated intrinsic value.

Global Bio-chem Technology Group Company Limited Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Global Bio-chem Technology Group Company Limited Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

Global Bio-chem Technology Group Company Limited Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Global Bio-chem Technology Group Company Limited Revenue
Year Revenue Growth
2000 1.208.026.000
2001 1.385.808.000 12.83%
2002 1.657.312.000 16.38%
2003 2.329.819.000 28.87%
2004 3.375.593.000 30.98%
2005 4.078.890.000 17.24%
2006 4.742.942.000 14%
2007 6.796.871.000 30.22%
2008 8.810.004.000 22.85%
2009 7.838.301.000 -12.4%
2010 9.314.898.000 15.85%
2011 14.438.887.000 35.49%
2012 11.908.082.000 -21.25%
2013 9.686.643.000 -22.93%
2014 6.399.205.000 -51.37%
2015 3.352.003.000 -90.91%
2016 3.882.840.000 13.67%
2017 4.397.005.000 11.69%
2018 5.657.726.000 22.28%
2019 4.561.391.000 -24.04%
2019 4.561.391.000 0%
2020 848.867.000 -437.35%
2021 746.551.000 -13.71%
2022 372.278.000 -100.54%
2023 1.373.938.000 72.9%
2024 3.594.164.000 61.77%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Global Bio-chem Technology Group Company Limited Research and Development Expenses
Year Research and Development Expenses Growth
2000 0
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 14.242.000 100%
2014 17.084.000 16.64%
2015 2.780.000 -514.53%
2016 11.338.000 75.48%
2017 10.567.000 -7.3%
2018 3.097.000 -241.2%
2019 0 0%
2019 17.625.000 100%
2020 14.786.000 -19.2%
2021 13.348.000 -10.77%
2022 10.229.000 -30.49%
2023 6.407.000 -59.65%
2024 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Global Bio-chem Technology Group Company Limited General and Administrative Expenses
Year General and Administrative Expenses Growth
2000 36.006.000
2001 64.852.000 44.48%
2002 73.713.000 12.02%
2003 95.456.000 22.78%
2004 115.940.000 17.67%
2005 118.056.000 1.79%
2006 152.893.000 22.79%
2007 222.657.000 31.33%
2008 287.266.000 22.49%
2009 264.951.000 -8.42%
2010 269.927.000 1.84%
2011 439.572.000 38.59%
2012 458.799.000 4.19%
2013 717.477.000 36.05%
2014 836.170.000 14.19%
2015 383.037.000 -118.3%
2016 347.562.000 -10.21%
2017 419.489.000 17.15%
2018 439.187.000 4.49%
2019 440.695.000 0.34%
2019 440.695.000 0%
2020 362.313.000 -21.63%
2021 372.761.000 2.8%
2022 328.207.000 -13.57%
2023 304.070.000 -7.94%
2024 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Global Bio-chem Technology Group Company Limited EBITDA
Year EBITDA Growth
2000 393.723.000
2001 535.983.000 26.54%
2002 688.037.000 22.1%
2003 925.267.000 25.64%
2004 1.394.425.000 33.65%
2005 862.164.000 -61.74%
2006 1.042.831.000 17.32%
2007 1.330.583.000 21.63%
2008 1.535.060.000 13.32%
2009 867.409.000 -76.97%
2010 1.386.711.000 37.45%
2011 2.816.886.000 50.77%
2012 699.231.000 -302.85%
2013 -1.527.009.000 145.79%
2014 -2.191.669.000 30.33%
2015 -1.136.654.000 -92.82%
2016 -1.175.247.000 3.28%
2017 -255.180.000 -360.56%
2018 -502.530.000 49.22%
2019 80.925.000 720.98%
2019 -473.016.000 117.11%
2020 -508.004.000 6.89%
2021 -571.335.000 11.08%
2022 -518.892.000 -10.11%
2023 -76.355.000 -579.58%
2024 184.124.000 141.47%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Global Bio-chem Technology Group Company Limited Gross Profit
Year Gross Profit Growth
2000 408.628.000
2001 556.347.000 26.55%
2002 650.795.000 14.51%
2003 864.958.000 24.76%
2004 1.299.335.000 33.43%
2005 1.051.358.000 -23.59%
2006 1.206.776.000 12.88%
2007 1.595.680.000 24.37%
2008 1.750.727.000 8.86%
2009 1.056.520.000 -65.71%
2010 1.567.359.000 32.59%
2011 3.367.435.000 53.46%
2012 1.531.991.000 -119.81%
2013 -900.887.000 270.05%
2014 -889.722.000 -1.25%
2015 -258.569.000 -244.09%
2016 315.822.000 181.87%
2017 609.031.000 48.14%
2018 259.710.000 -134.5%
2019 203.529.000 -27.6%
2019 203.529.000 0%
2020 74.100.000 -174.67%
2021 48.351.000 -53.25%
2022 34.597.000 -39.75%
2023 43.637.000 20.72%
2024 264.100.000 83.48%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Global Bio-chem Technology Group Company Limited Net Profit
Year Net Profit Growth
2000 230.168.000
2001 330.078.000 30.27%
2002 405.095.000 18.52%
2003 520.772.000 22.21%
2004 815.451.000 36.14%
2005 466.484.000 -74.81%
2006 501.228.000 6.93%
2007 979.854.000 48.85%
2008 621.777.000 -57.59%
2009 -14.978.000 4251.27%
2010 331.726.000 104.52%
2011 1.309.798.000 74.67%
2012 -554.508.000 336.21%
2013 -6.081.097.000 90.88%
2014 -3.371.388.000 -80.37%
2015 -1.995.970.000 -68.91%
2016 -1.850.640.000 -7.85%
2017 -837.491.000 -120.97%
2018 -1.222.322.000 31.48%
2019 -1.116.334.000 -9.49%
2019 -1.116.334.000 0%
2020 -2.433.266.000 54.12%
2021 -435.389.000 -458.87%
2022 -1.519.565.000 71.35%
2023 4.224.593.000 135.97%
2024 -630.972.000 769.54%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Global Bio-chem Technology Group Company Limited Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2000 0
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 -2 100%
2014 -1 0%
2015 -1 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Global Bio-chem Technology Group Company Limited Free Cashflow
Year Free Cashflow Growth
2000 -22.928.000
2001 -10.098.000 -127.05%
2002 -129.003.000 92.17%
2003 -134.406.000 4.02%
2004 -557.536.000 75.89%
2005 35.646.000 1664.09%
2006 -791.606.000 104.5%
2007 -597.348.000 -32.52%
2008 -527.561.000 -13.23%
2009 -787.223.000 32.98%
2010 -1.924.927.000 59.1%
2011 156.446.000 1330.41%
2012 -226.000 69323.89%
2013 360.328.000 100.06%
2014 457.910.000 21.31%
2015 -379.379.000 220.7%
2016 -313.430.000 -21.04%
2017 -68.257.000 -359.19%
2018 -233.231.000 70.73%
2019 159.888.000 245.87%
2019 39.972.000 -300%
2020 -43.016.000 192.92%
2021 -501.019.000 91.41%
2022 -94.186.000 -431.95%
2023 2.266.000 4256.49%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Global Bio-chem Technology Group Company Limited Operating Cashflow
Year Operating Cashflow Growth
2000 121.201.000
2001 443.718.000 72.69%
2002 349.544.000 -26.94%
2003 536.736.000 34.88%
2004 705.905.000 23.96%
2005 1.846.902.000 61.78%
2006 582.554.000 -217.04%
2007 400.689.000 -45.39%
2008 531.948.000 24.68%
2009 -255.935.000 307.84%
2010 -857.603.000 70.16%
2011 2.218.826.000 138.65%
2012 2.110.537.000 -5.13%
2013 520.288.000 -305.65%
2014 646.821.000 19.56%
2015 -284.334.000 327.49%
2016 -143.756.000 -97.79%
2017 267.290.000 153.78%
2018 -64.497.000 514.42%
2019 211.316.000 130.52%
2019 52.829.000 -300%
2020 -26.186.000 301.75%
2021 -475.207.000 94.49%
2022 -88.010.000 -439.95%
2023 45.008.000 295.54%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Global Bio-chem Technology Group Company Limited Capital Expenditure
Year Capital Expenditure Growth
2000 144.129.000
2001 453.816.000 68.24%
2002 478.547.000 5.17%
2003 671.142.000 28.7%
2004 1.263.441.000 46.88%
2005 1.811.256.000 30.25%
2006 1.374.160.000 -31.81%
2007 998.037.000 -37.69%
2008 1.059.509.000 5.8%
2009 531.288.000 -99.42%
2010 1.067.324.000 50.22%
2011 2.062.380.000 48.25%
2012 2.110.763.000 2.29%
2013 159.960.000 -1219.56%
2014 188.911.000 15.33%
2015 95.045.000 -98.76%
2016 169.674.000 43.98%
2017 335.547.000 49.43%
2018 168.734.000 -98.86%
2019 51.428.000 -228.1%
2019 12.857.000 -300%
2020 16.830.000 23.61%
2021 25.812.000 34.8%
2022 6.176.000 -317.94%
2023 42.742.000 85.55%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Global Bio-chem Technology Group Company Limited Equity
Year Equity Growth
2000 367.037.000
2001 1.424.048.000 74.23%
2002 2.054.787.000 30.7%
2003 2.813.489.000 26.97%
2004 4.623.895.000 39.15%
2005 4.738.572.000 2.42%
2006 5.047.499.000 6.12%
2007 6.886.019.000 26.7%
2008 7.900.475.000 12.84%
2009 8.038.663.000 1.72%
2010 9.672.875.000 16.89%
2011 11.862.540.000 18.46%
2012 11.238.176.000 -5.56%
2013 5.094.908.000 -120.58%
2014 1.257.890.000 -305.04%
2015 24.076.000 -5124.66%
2016 -1.804.067.000 101.33%
2017 -2.466.524.000 26.86%
2018 -3.570.534.000 30.92%
2019 -4.345.991.000 17.84%
2020 -6.017.075.000 27.77%
2021 -6.700.825.000 10.2%
2022 -7.787.056.000 13.95%
2023 -4.036.906.000 -92.9%
2023 -7.487.877.000 46.09%
2024 -2.697.317.000 -177.6%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Global Bio-chem Technology Group Company Limited Assets
Year Assets Growth
2000 1.193.601.000
2001 2.028.575.000 41.16%
2002 2.733.098.000 25.78%
2003 4.228.443.000 35.36%
2004 6.844.884.000 38.22%
2005 9.402.985.000 27.21%
2006 10.574.200.000 11.08%
2007 13.397.560.000 21.07%
2008 15.441.985.000 13.24%
2009 17.010.097.000 9.22%
2010 19.835.098.000 14.24%
2011 23.750.728.000 16.49%
2012 22.934.334.000 -3.56%
2013 18.784.740.000 -22.09%
2014 13.756.393.000 -36.55%
2015 12.579.801.000 -9.35%
2016 9.833.188.000 -27.93%
2017 10.763.086.000 8.64%
2018 9.824.839.000 -9.55%
2019 8.234.929.000 -19.31%
2020 7.601.594.000 -8.33%
2021 6.482.715.000 -17.26%
2022 5.849.887.000 -10.82%
2023 5.209.096.000 -12.3%
2023 5.608.607.000 7.12%
2024 4.864.083.000 -15.31%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Global Bio-chem Technology Group Company Limited Liabilities
Year Liabilities Growth
2000 826.564.000
2001 604.527.000 -36.73%
2002 678.311.000 10.88%
2003 1.414.954.000 52.06%
2004 2.220.989.000 36.29%
2005 4.664.413.000 52.38%
2006 5.526.701.000 15.6%
2007 6.511.541.000 15.12%
2008 7.541.510.000 13.66%
2009 8.971.434.000 15.94%
2010 10.162.223.000 11.72%
2011 11.888.188.000 14.52%
2012 11.696.158.000 -1.64%
2013 13.689.832.000 14.56%
2014 12.498.503.000 -9.53%
2015 12.555.725.000 0.46%
2016 11.637.255.000 -7.89%
2017 13.229.610.000 12.04%
2018 13.395.373.000 1.24%
2019 12.580.920.000 -6.47%
2020 13.618.669.000 7.62%
2021 13.183.540.000 -3.3%
2022 13.636.943.000 3.32%
2023 9.246.002.000 -47.49%
2023 13.096.484.000 29.4%
2024 7.561.400.000 -73.2%

Global Bio-chem Technology Group Company Limited Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.18
Net Income per Share
0.46
Price to Earning Ratio
0.16x
Price To Sales Ratio
0.4x
POCF Ratio
-6.27
PFCF Ratio
-4.41
Price to Book Ratio
-0.24
EV to Sales
2.02
EV Over EBITDA
91.03
EV to Operating CashFlow
-31.42
EV to FreeCashFlow
-22.1
Earnings Yield
6.35
FreeCashFlow Yield
-0.23
Market Cap
0,65 Bil.
Enterprise Value
3,26 Bil.
Graham Number
1.78
Graham NetNet
-0.79

Income Statement Metrics

Net Income per Share
0.46
Income Quality
-0.03
ROE
-1.23
Return On Assets
0.85
Return On Capital Employed
0.1
Net Income per EBT
1.12
EBT Per Ebit
-20.63
Ebit per Revenue
-0.11
Effective Tax Rate
-0

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.09
Operating Profit Margin
-0.11
Pretax Profit Margin
2.28
Net Profit Margin
2.57

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.01
Free CashFlow per Share
-0.02
Capex to Operating CashFlow
-0.42
Capex to Revenue
0.03
Capex to Depreciation
0.18
Return on Invested Capital
7.89
Return on Tangible Assets
0.85
Days Sales Outstanding
79.99
Days Payables Outstanding
264.18
Days of Inventory on Hand
75.2
Receivables Turnover
4.56
Payables Turnover
1.38
Inventory Turnover
4.85
Capex per Share
0

Balance Sheet

Cash per Share
0,01
Book Value per Share
-0,30
Tangible Book Value per Share
-0.3
Shareholders Equity per Share
-0.3
Interest Debt per Share
0.36
Debt to Equity
-0.99
Debt to Assets
0.55
Net Debt to EBITDA
72.87
Current Ratio
0.12
Tangible Asset Value
-2,70 Bil.
Net Current Asset Value
-6,73 Bil.
Invested Capital
-1854201000
Working Capital
-5,84 Bil.
Intangibles to Total Assets
0
Average Receivables
0,37 Bil.
Average Payables
0,98 Bil.
Average Inventory
224782500
Debt to Market Cap
4.11

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Global Bio-chem Technology Group Company Limited Dividends
Year Dividends Growth
2001 0
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2011 0 0%
2012 0 0%

Global Bio-chem Technology Group Company Limited Profile

About Global Bio-chem Technology Group Company Limited

Global Bio-chem Technology Group Company Limited, an investment holding company, manufactures and sells corn refined products and corn-based biochemical products in the People's Republic of China, rest of Asia, the Americas, and internationally. It operates through four segments: Upstream Products, Amino Acids, Corn Sweeteners, and Polyol Chemicals. The company offers corn refined products, including corn oil, corn steep liquor, corn starch, waxy corn starch, corn gluten meal, feed pellets, and corn germ cake. It also provides downstream corn based biochemical products, such as amino acids comprising lysine, protein lysine, threonine, and glutamic acid; corn sweeteners, which include high fructose corn syrup, maltodextrin, high maltose syrup, maltose syrup, sorbitol, glucose, and crystallized glucose; modified starches; and chemicals comprising ethylene, propylene, and butylene glycols, as well as resins. In addition, the company offers anti-freeze products, hydrogen, and ammonia. Its products are used in various applications, such as feed production, food and beverage, cosmetics, textiles, pharmaceuticals, chemical industries, etc. The company was founded in 1994 and is headquartered in Hung Hom, Hong Kong.

CEO
Mr. Cheng Wang
Employee
2.600
Address
Tower A, Cheung Kei Center
Hung Hom,

Global Bio-chem Technology Group Company Limited Executives & BODs

Global Bio-chem Technology Group Company Limited Executives & BODs
# Name Age
1 Mr. Yu Feng Sha
Chief Accountant
70
2 Mr. Cheng Wang
Executive Chairman
70
3 Mr. Sing Fai Chan A.C.S.
Company Secretary & Financial Controller
70
4 Mr. Guicheng Wang
Chief Operating Officer & Executive Director
70

Global Bio-chem Technology Group Company Limited Competitors